Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 4, 2023

Primary Completion Date

October 15, 2025

Study Completion Date

June 15, 2026

Conditions
Gastric Cancer
Interventions
DRUG

AST-301

100 μg

DRUG

rhuGM-CSF

100 μg

Trial Locations (6)

112

RECRUITING

Taipei Veterans General Hospital, Taipei

333

RECRUITING

Chang Gung Memorial Hospital Linkou, Taoyuan District

404

RECRUITING

China Medical University Hospital, Taichung

710

RECRUITING

Chi Mei Medical Center, Tainan City

40705

RECRUITING

Taichung Veterans General Hospital, Taichung

80756

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Aston Sci. Inc.

INDUSTRY

NCT05771584 - Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer | Biotech Hunter | Biotech Hunter